Trial Profile
Efficacy of certolizumab substituted for infliximab or adalimumab in patients with Crohn's disease: A single-center, retrospective cohort study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2018
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SAVANT
- 09 Mar 2018 New trial record